HUE049600T2 - GLS1 inhibitorok betegségek kezelésére - Google Patents

GLS1 inhibitorok betegségek kezelésére

Info

Publication number
HUE049600T2
HUE049600T2 HUE15814723A HUE15814723A HUE049600T2 HU E049600 T2 HUE049600 T2 HU E049600T2 HU E15814723 A HUE15814723 A HU E15814723A HU E15814723 A HUE15814723 A HU E15814723A HU E049600 T2 HUE049600 T2 HU E049600T2
Authority
HU
Hungary
Prior art keywords
treating diseases
gls1 inhibitors
gls1
inhibitors
diseases
Prior art date
Application number
HUE15814723A
Other languages
English (en)
Inventor
Francesco Maria Di
Philip Jones
Timothy Heffernan
Matthew Hamilton
Zhijun Kang
Michael Soth
Jason Burke
Kang Le
Christopher Carroll
Wylie Palmer
Richard Lewis
Timothy Mcafoos
Barbara Czako
Gang Liu
Jay Theroff
Zachary Herrera
Anne Yau
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of HUE049600T2 publication Critical patent/HUE049600T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE15814723A 2014-07-03 2015-07-02 GLS1 inhibitorok betegségek kezelésére HUE049600T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462020539P 2014-07-03 2014-07-03

Publications (1)

Publication Number Publication Date
HUE049600T2 true HUE049600T2 (hu) 2020-10-28

Family

ID=55020106

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15814723A HUE049600T2 (hu) 2014-07-03 2015-07-02 GLS1 inhibitorok betegségek kezelésére

Country Status (17)

Country Link
US (5) US9809588B2 (hu)
EP (2) EP3164394B1 (hu)
JP (2) JP6619758B2 (hu)
CN (1) CN107074805B (hu)
AU (1) AU2015283850B2 (hu)
BR (1) BR112016030730B1 (hu)
CA (1) CA2953989C (hu)
CY (1) CY1123216T1 (hu)
DK (1) DK3164394T3 (hu)
ES (1) ES2788449T3 (hu)
HU (1) HUE049600T2 (hu)
LT (1) LT3164394T (hu)
NZ (1) NZ726695A (hu)
PL (1) PL3164394T3 (hu)
PT (1) PT3164394T (hu)
SI (1) SI3164394T1 (hu)
WO (1) WO2016004404A2 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049600T2 (hu) 2014-07-03 2020-10-28 Univ Texas GLS1 inhibitorok betegségek kezelésére
US20160002204A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating disease
EP3316887B1 (en) 2015-06-30 2020-04-08 Board of Regents, The University of Texas System Gls1 inhibitors for treating disease
RU2018124266A (ru) 2015-12-22 2020-01-23 Боард Оф Реджентс, Де Юниверсити Оф Техас Систем Солевые формы и полиморфы (R)-1-(4-(6-(2-(4-(3,3-дифторциклобутокси)-6-метилпиридин-2-ил)ацетамидо)пиридазин-3-ил)-2- фторбутил) -N-метил-1Н-1,2,3-триазол-4-карбоксамид
WO2018110669A1 (en) * 2016-12-15 2018-06-21 Ono Pharmaceutical Co., Ltd. Activator of trek (twik related k+ channels) channels
RU2020112558A (ru) 2017-10-18 2021-11-18 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Терапия на основе ингибитора глутаминазы
CN109988124B (zh) * 2017-12-29 2024-01-09 杭州健昵福生物科技有限公司 一种含氧族元素二唑或四氮唑结构的肾型谷氨酰胺酶变构位点的抑制剂
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN117043153A (zh) * 2020-12-11 2023-11-10 杭州紫晶医药科技有限公司 作为gls1抑制剂的杂环化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES498337A0 (es) 1980-01-07 1982-06-01 Nyegaard & Co As Un procedimiento para la preparacion de 5-halo-pirimidin-2- onas
EP0218753B1 (en) 1985-10-10 1989-08-09 Agfa-Gevaert N.V. Image-recieving element for the silver salt diffusion transfer reversal process
US4920125A (en) * 1989-08-29 1990-04-24 The Trustees Of Princeton University L-glutamic acid derivatives
WO1991009848A1 (en) 1989-12-22 1991-07-11 The Upjohn Company Pyridinones useful as antiatherosclerotic agents
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
CN1318029C (zh) 1995-07-21 2007-05-30 巧妙疗法股份有限公司 氨基咪唑甲酰胺和5－氨基或取代的氨基1,2,3－三唑的盐在制备治疗和预防肿瘤的药物组合物中的用途
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
JP2001524481A (ja) * 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
CA2406745C (en) 2001-11-13 2006-01-10 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
US7985548B2 (en) 2006-03-03 2011-07-26 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CA2686933A1 (en) 2007-04-06 2008-10-16 The Johns Hopkins University Methods and compositions for the treatment of cancer
RU2503676C2 (ru) 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Пирролопиразиновые ингибиторы киназы
SI2300013T1 (en) 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP2011231015A (ja) 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk 含窒素複素環を有する新規ウラシル化合物又はその塩
BRPI1007836A2 (pt) 2009-02-27 2015-09-01 Enanta Phamaceuticals Inc Inibidores do vírus c da hepatite
WO2010111504A2 (en) 2009-03-25 2010-09-30 Cornell University Inhibition of glutaminase c
JP5725475B2 (ja) 2010-01-21 2015-05-27 公立大学法人名古屋市立大学 ヒドロキサム酸誘導体及びそれを用いたｈｄａｃ８阻害剤
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
SG10201607685SA (en) * 2011-11-21 2016-11-29 Calithera Biosciences Inc Heterocyclic inhibitors of glutaminase
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
SG11201503720SA (en) * 2012-11-16 2015-06-29 Calithera Biosciences Inc Heterocyclic glutaminase inhibitors
EP2922832B1 (en) * 2012-11-21 2019-10-09 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2014089048A1 (en) 2012-12-03 2014-06-12 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
KR102161867B1 (ko) * 2013-01-30 2020-10-05 스미또모 가가꾸 가부시끼가이샤 유해 절족동물의 방제 방법
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物
EP3092235A2 (en) 2014-01-06 2016-11-16 Rhizen Pharmaceuticals S.A. Novel inhibitors of glutaminase
US20160002248A1 (en) 2014-07-03 2016-01-07 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating disease
US20160002204A1 (en) 2014-07-03 2016-01-07 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating disease
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
HUE049600T2 (hu) 2014-07-03 2020-10-28 Univ Texas GLS1 inhibitorok betegségek kezelésére
US20160058759A1 (en) 2014-07-03 2016-03-03 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
EP3316887B1 (en) 2015-06-30 2020-04-08 Board of Regents, The University of Texas System Gls1 inhibitors for treating disease
RU2018124266A (ru) 2015-12-22 2020-01-23 Боард Оф Реджентс, Де Юниверсити Оф Техас Систем Солевые формы и полиморфы (R)-1-(4-(6-(2-(4-(3,3-дифторциклобутокси)-6-метилпиридин-2-ил)ацетамидо)пиридазин-3-ил)-2- фторбутил) -N-метил-1Н-1,2,3-триазол-4-карбоксамид
RU2020112558A (ru) 2017-10-18 2021-11-18 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Терапия на основе ингибитора глутаминазы

Also Published As

Publication number Publication date
BR112016030730A8 (pt) 2021-07-20
US10344025B2 (en) 2019-07-09
US9809588B2 (en) 2017-11-07
PT3164394T (pt) 2020-05-08
US10766892B2 (en) 2020-09-08
AU2015283850B2 (en) 2020-06-04
SI3164394T1 (sl) 2020-08-31
EP3164394A2 (en) 2017-05-10
ES2788449T3 (es) 2020-10-21
WO2016004404A2 (en) 2016-01-07
JP2017522294A (ja) 2017-08-10
CY1123216T1 (el) 2021-10-29
US20200407353A1 (en) 2020-12-31
CN107074805B (zh) 2021-02-26
BR112016030730B1 (pt) 2023-05-02
US20160009704A1 (en) 2016-01-14
US20230124815A1 (en) 2023-04-20
AU2015283850A1 (en) 2016-12-15
EP3677579A1 (en) 2020-07-08
CN107074805A (zh) 2017-08-18
EP3164394B1 (en) 2020-04-01
NZ726695A (en) 2024-02-23
EP3164394A4 (en) 2018-02-28
CA2953989C (en) 2023-10-10
BR112016030730A2 (pt) 2017-08-22
PL3164394T3 (pl) 2020-09-07
US20170291895A1 (en) 2017-10-12
LT3164394T (lt) 2020-05-25
US20190270736A1 (en) 2019-09-05
CA2953989A1 (en) 2016-01-07
US11958849B2 (en) 2024-04-16
DK3164394T3 (da) 2020-05-04
JP2020059715A (ja) 2020-04-16
JP6619758B2 (ja) 2019-12-11
US11370786B2 (en) 2022-06-28
WO2016004404A3 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating eye diseases
IL287113A (en) smyd inhibitors
IL285201A (en) EZH2 inhibitors for the treatment of lymphoma
IL253945B (en) kdm1a inhibitors to treat the disease
SG11201705093UA (en) Composition for treating il-6-related diseases
AP2016009371A0 (en) Benzimidazol-2-amines as midh1 inhibitors
IL278247B (en) mct4 inhibitors to treat the disease
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
HK1253238A1 (zh) 用於治療疾病的gls1抑制劑
HK1244217A1 (zh) 用於治療蛋白質病的方法
HUE049600T2 (hu) GLS1 inhibitorok betegségek kezelésére
SG11201609350XA (en) Methods for inhibiting necroptosis
IL251790B (en) Compounds include thiazole for the treatment of culture diseases
IL246558A0 (en) New methods of cancer treatment
SG11201609522TA (en) Methods for treating cardiovascular diseases
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
IL249616A0 (en) Methods for treating inflammation
GB201418154D0 (en) Inhibitors